Glass delamination resulting in barely visible glass flakes has led to recalls of numerous injectable drug products over the past few years. In order to prioritize patient safety, the FDA has reacted to this phenomenon by emphazising the importance of container/drug compatibility testing in line with USP 1660.
SCHOTT EVERIC™ – An optimized manufacturing process combined with quantitative laboratory test procedures on delamination resistance has proven to significantly reduce the risk of glass delamination.
Chemically homogenious inner surface thanks to cutting-edge hot forming technology
SCHOTT patented Quicktest to verify the reduced delamination risk of each production batch using a predefine quantitative limit value
Reproducibly improved chemical stability of container’s inner surface
Significantly reduced delamination risk
Applicable to all products already registered – hence no re-registration required